Literature DB >> 27485397

Expression of cyclooxygenases and trophic and growth factors in epiretinal membranes at late stages of proliferative vitreoretinopathy.

Marina Tikhonovich1, Pavel Lyskin2, Elena Ioyleva2, Svetlana Gavrilova3.   

Abstract

Entities:  

Keywords:  BDNF; Cyclooxygenase; Membrane; NGF; Proliferative vitreoretinopathy; VEGF

Mesh：

Substances：

Year:  2016        PMID： 27485397     DOI： 10.1007/s00417-016-3445-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells.

Authors:  C E Bryant; I Appleton; J A Mitchell
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

2.  Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells.

Authors:  Frauke Forstreuter; Ralph Lucius; Rolf Mentlein
Journal:  J Neuroimmunol       Date:  2002-11       Impact factor: 3.478

3.  Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats.

Authors:  Simone Böcker-Meffert; Philip Rosenstiel; Claudia Röhl; Nils Warneke; Janka Held-Feindt; Jobst Sievers; Ralph Lucius
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-06       Impact factor: 4.799

4.  Cyclo-oxygenase-2 expression in human idiopathic epiretinal membrane.

Authors:  Satoru Kase; Wataru Saito; Shigeaki Ohno; Susumu Ishida
Journal:  Retina       Date:  2010-05       Impact factor: 4.256

5.  Growth factor combinations modulate human retinal pigment epithelial cell proliferation.

Authors:  C W Kaven; C W Spraul; N K Zavazava; G K Lang; G E Lang
Journal:  Curr Eye Res       Date:  2000-06       Impact factor: 2.424

6.  Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients.

Authors:  Shawn C Maloney; Bruno F Fernandes; Enzo Castiglione; Emilia Antecka; Claudia Martins; Jean-Claude Marshall; Sebastian Di Cesare; Patrick Logan; Miguel N Burnier
Journal:  Retina       Date:  2009-02       Impact factor: 4.256

7.  Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells.

Authors:  S Mansour-Robaey; D B Clarke; Y C Wang; G M Bray; A J Aguayo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

8.  Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain.

Authors:  Abner Louissaint; Sudha Rao; Caroline Leventhal; Steven A Goldman
Journal:  Neuron       Date:  2002-06-13       Impact factor: 17.173

9.  Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors.

Authors:  Magali Saint-Geniez; Arindel S R Maharaj; Tony E Walshe; Budd A Tucker; Eiichi Sekiyama; Tomoki Kurihara; Diane C Darland; Michael J Young; Patricia A D'Amore
Journal:  PLoS One       Date:  2008-11-03       Impact factor: 3.240

10.  Intravitreal NGF administration counteracts retina degeneration after permanent carotid artery occlusion in rat.

Authors:  Sandra Sivilia; Alessandro Giuliani; Mercedes Fernández; Maria Elena Turba; Monica Forni; Alessandro Massella; Nadia De Sordi; Luciana Giardino; Laura Calzà
Journal:  BMC Neurosci       Date:  2009-05-27       Impact factor: 3.288
  10 in total
  3 in total

1.  Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one.

Authors:  Marina V Tikhonovich; Aleksei K Erdiakov; Svetlana A Gavrilova
Journal:  Int Ophthalmol       Date:  2017-06-21       Impact factor: 2.031

2.  The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy.

Authors:  Rui Zhang; Xin Sun; Bo Niu
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

Review 3.  Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review.

Authors:  Ying Dai; Chenghua Dai; Tao Sun
Journal:  Int Ophthalmol       Date:  2020-02-26       Impact factor: 2.031
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.